Epizyme shares slump as cancer drug data update disappoints

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Epizyme shares slump as cancer drug data update disappoints

posted on Jun 14, 2017 11:16AM

Epizyme's EZH2 inhibitor, an epigenetic cousin to the BET inhibitors, yields somewhat disappointing results.

Epizyme shares slump as cancer drug data update disappoints

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply